Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

Tiklamalar: 460
ID: 274575
1997
Ucretsiz PDF
Makale Kalitesi ve Performans Metrikleri
Genel Kalite Improving Quality
0.0 /100
Etkilesim verilerini yapay zeka tabanli akademik kalite degerlendirmesiyle birlestirir
Yapay Zeka Kalite Degerlendirmesi
Analiz edilmedi
Ozet
Transdermal nicotine administered at the highest tolerated dosage (< or = 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.
Referans Anahtari
wj1997annalstransdermal Kullanarak makale yazarken otomatik alinti icin bu anahtari kullanin SciMatic Makale Yoneticisi veya Tez Yoneticisi
Yazarlar Sandborn WJ;Tremaine WJ;Offord KP;Lawson GM;Petersen BT;Batts KP;Croghan IT;Dale LC;Schroeder DR;Hurt RD;;
Dergi annals of internal medicine
Yil 1997
DOI
DOI bulunamadi
URL
https://www.pubmed.gov/9054280/
Anahtar Kelimeler
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male adolescent aged middle aged Remission Induction Clinical Trial Randomized Controlled Trial Double-Blind Method placebos Colitis Ulcerative / drug therapy* cutaneous dermatitis ulcerative / blood w j sandborn pmid:9054280 doi:10.7326/0003-4819-126-5-199703010-00004 w j tremaine r d hurt cotinine / blood contact / etiology nausea / chemically induced nicotine / administration & dosage* nicotine / adverse effects nicotine / blood

Atiflar

Atif bulunamadi. Atif eklemek icin yoneticiyle iletisime gecin: info@scimatic.org

Yorumlar

Henuz yorum yok. Bu makaleye ilk yorumu siz yapin.